Table 1 Demographic and clinical characteristics of the study population
Variables | Total (N = 95) | Recurrence (N = 26) | No-Recurrence (N = 69) | P value |
|---|---|---|---|---|
Demographics | ||||
 Age (years) | 63.2 ± 9.7 | 60.7 ± 8.4 | 64.2 ± 10.0 | 0.110 |
 Man, n (%) | 54 (56.8%) | 15 (57.7%) | 39 (56.5%) | 0.919 |
 BSA (/m2) | 1.81 ± 0.17 | 1.83 ± 0.15 | 1.81 ± 0.17 | 0.564 |
 BMI (kg/ m2) | 25.8 ± 3.3 | 25.7 ± 3.4 | 25.9 ± 3.3 | 0.849 |
AF characteristics | ||||
 Paroxysmal AF, n (%) | 67 (70.5%) | 17 (65.4%) | 50 (72.5%) | 0.502 |
 Persistent AF, n (%) | 28 (29.5%) | 9 (34.6%) | 19 (27.5%) | 0.502 |
 CHA2DS2-VASc score ≥ 2 | 61 (64.2%) | 16 (61.5%) | 45 (65.2%) | 0.740 |
 HASBLED score ≥ 3 | 25 (26.3%) | 8 (30.8%) | 17 (24.6%) | 0.547 |
 First catheter ablation | 85 (89.5%) | 22 (84.6%) | 63 (91.3%) | 0.453 |
Medical history, n (%) | ||||
 Hypertension | 60 (63.2%) | 17 (65.4%) | 43 (62.3%) | 0.784 |
 Diabetes mellitus | 18 (18.9%) | 8 (30.8%) | 10 (14.5%) | 0.073 |
 History of ischemic heart disease | 41 (45.5%) | 10 (38.5%) | 31 (44.9%) | 0.573 |
 Hyperlipidemia | 70 (73.7%) | 18 (69.2%) | 52 (75.4%) | 0.547 |
 Stroke, TIA or thromboembolism | 20 (21.5%) | 6 (23.1%) | 14 (20.3%) | 0.782 |
 Cigarette | 33 (34.7%) | 11 (42.3%) | 22 (31.9%) | 0.344 |
 Alcohol | 29 (30.5%) | 11 (42.3%) | 18 (26.1%) | 0.128 |
Medications, n (%) | ||||
 Antiarrhythmic drugs | 79 (83.2%) | 19 (73.1%) | 60 (87.0%) | 0.109 |
 Anticoagulation therapy | 93 (97.9%) | 26 (100%) | 67 (97.1%) | 0.383 |
 Aspirin | 26 (27.4%) | 8 (30.8%) | 18 (26.1%) | 0.650 |
 Calcium channel blockers | 36 (37.9%) | 11 (42.3%) | 25 (36.2%) | 0.588 |
 ACEi/ARB | 40 (42.1%) | 14 (53.8%) | 26 (37.7%) | 0.157 |
 Beta blocker | 58 (61.1%) | 17 (65.4%) | 41 (59.4%) | 0.597 |